Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction

Y. Desai, Milind; Owens, Anjali; Wolski, Kathy; B. Geske, Jeffrey; Saberi, Sara; Wang, Andrew; V. Sherrid, Mark; Cremer, Paul; K. Lakdawala, Neal; Tower‐Rader, Albree; Fermin, David; S. Naidu, Srihari; G. Smedira, Nicholas; V. Schaff, Hartzell; McErlean, Ellen; Sewell, Christina; Mudarris, Lana; Gong, Zhiqun; Lampl, Kathy; J. Sehnert, Amy; E. Nissen, Steven

doi:10.1001/jamacardio.2023.3342

Public

Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction

Published in JAMA Cardiology • Aug 28, 2023

Authors:

Milind Y. Desai

Anjali Owens

Kathy Wolski

Abstract

Importance: There is an unmet need for novel medical therapies before recommending invasive therapies for patients with severely symptomatic obstructive hypertrophic cardiomyopathy (HCM). Mavacamten has been shown to improve left ventricular outflow tract (LVOT) gradient and symptoms and may thus re...

Subject

Medicine

Ejection fraction

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!